Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

医学 内科学 化疗 拓扑替康 置信区间 卵巢癌 优势比 肿瘤科 随机化 无进展生存期 随机对照试验 卡铂 外科 胃肠病学 癌症 顺铂
作者
Kathleen N. Moore,Antoine Angelergues,Gottfried E. Konecny,Yolanda García García,Susana Banerjee,Domenica Lorusso,Jung‐Yun Lee,John W. Moroney,Nicoletta Colombo,A. Roszak,Jacqueline M. Tromp,Tashanna Myers,Jeong‐Won Lee,Mario Beiner,Casey Cosgrove,David Cibula,Lainie P. Martin,Renaud Sabatier,Joseph Buscema,Purificación Estévez-García
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:389 (23): 2162-2174 被引量:136
标识
DOI:10.1056/nejmoa2309169
摘要

Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant ovarian cancer in the United States.We conducted a phase 3, global, confirmatory, open-label, randomized, controlled trial to compare the efficacy and safety of MIRV with the investigator's choice of chemotherapy in the treatment of platinum-resistant, high-grade serous ovarian cancer. Participants who had previously received one to three lines of therapy and had high FRα tumor expression (≥75% of cells with ≥2+ staining intensity) were randomly assigned in a 1:1 ratio to receive MIRV (6 mg per kilogram of adjusted ideal body weight every 3 weeks) or chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan). The primary end point was investigator-assessed progression-free survival; key secondary analytic end points included objective response, overall survival, and participant-reported outcomes.A total of 453 participants underwent randomization; 227 were assigned to the MIRV group and 226 to the chemotherapy group. The median progression-free survival was 5.62 months (95% confidence interval [CI], 4.34 to 5.95) with MIRV and 3.98 months (95% CI, 2.86 to 4.47) with chemotherapy (P<0.001). An objective response occurred in 42.3% of the participants in the MIRV group and in 15.9% of those in the chemotherapy group (odds ratio, 3.81; 95% CI, 2.44 to 5.94; P<0.001). Overall survival was significantly longer with MIRV than with chemotherapy (median, 16.46 months vs. 12.75 months; hazard ratio for death, 0.67; 95% CI, 0.50 to 0.89; P = 0.005). During the treatment period, fewer adverse events of grade 3 or higher occurred with MIRV than with chemotherapy (41.7% vs. 54.1%), as did serious adverse events of any grade (23.9% vs. 32.9%) and events leading to discontinuation (9.2% vs. 15.9%).Among participants with platinum-resistant, FRα-positive ovarian cancer, treatment with MIRV showed a significant benefit over chemotherapy with respect to progression-free and overall survival and objective response. (Funded by ImmunoGen; MIRASOL ClinicalTrials.gov number, NCT04209855.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
脑洞疼应助fj采纳,获得10
1秒前
宁秘发布了新的文献求助10
1秒前
2秒前
量子星尘发布了新的文献求助10
2秒前
Mingchun发布了新的文献求助10
3秒前
寒冷如冬完成签到,获得积分10
4秒前
大模型应助wjx采纳,获得10
4秒前
Ava应助wjx采纳,获得10
5秒前
充电宝应助wjx采纳,获得10
5秒前
李健的粉丝团团长应助wjx采纳,获得10
5秒前
zxs完成签到,获得积分10
5秒前
陈月月鸟应助wjx采纳,获得10
5秒前
传奇3应助wjx采纳,获得10
5秒前
可爱的函函应助wjx采纳,获得10
5秒前
深情安青应助wjx采纳,获得10
5秒前
JamesPei应助wjx采纳,获得10
5秒前
壮观的猎豹完成签到 ,获得积分10
5秒前
qingmao完成签到,获得积分10
6秒前
7秒前
zxs发布了新的文献求助10
7秒前
123456发布了新的文献求助10
8秒前
Mingchun完成签到,获得积分10
8秒前
聪慧的草丛完成签到 ,获得积分10
8秒前
小唐尼完成签到,获得积分10
9秒前
工藤新一完成签到,获得积分10
9秒前
啦啦发布了新的文献求助10
11秒前
12秒前
qq完成签到,获得积分10
12秒前
iris发布了新的文献求助10
13秒前
打打应助cc采纳,获得10
14秒前
14秒前
15秒前
16秒前
冰凉发布了新的文献求助10
17秒前
zsy发布了新的文献求助10
18秒前
18秒前
独特冰安发布了新的文献求助10
18秒前
21秒前
SSS水鱼发布了新的文献求助10
21秒前
24秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975426
求助须知:如何正确求助?哪些是违规求助? 3519848
关于积分的说明 11199831
捐赠科研通 3256122
什么是DOI,文献DOI怎么找? 1798124
邀请新用户注册赠送积分活动 877386
科研通“疑难数据库(出版商)”最低求助积分说明 806305